Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernhard Gerber

Showing results (111-120 of 138) with videos related to

Pageof 14
Sort By:
The Lancet. Haematology|July 2, 2022
Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trialStefano Barco, Davide Voci, Ulrike Held, et al.
Bone Marrow Transplantation|November 4, 2018
Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry studyGuido Ghilardi, Thomas Pabst, Barbara Jeker, et al.
American Journal of Hematology|June 8, 2026
Determinants of Long-Term Benefit From High Dose Melphalan With Autologous Stem Cell Transplant in AL AmyloidosisMaximilian J Steinhardt, Ute Hegenbart, Tamer Hellou, et al.
European Heart Journal. Cardiovascular Imaging|July 12, 2024
Survival loss linked to guideline-based indications for degenerative mitral regurgitation surgeryDavid Vancraeynest, Anne-Catherine Pouleur, Christophe de Meester, et al.
European Heart Journal. Cardiovascular Imaging|April 4, 2020
COVID-19 pandemic and cardiac imaging: EACVI recommendations on precautions, indications, prioritization, and protection for patients and healthcare personnelHelge Skulstad, Bernard Cosyns, Bogdan A Popescu, et al.
Thrombosis Research|November 17, 2022
Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trialDavide Voci, Andrea Götschi, Ulrike Held, et al.
JACC. Basic to Translational Science|November 27, 2019
Platelet Acetyl-CoA Carboxylase Phosphorylation: A Risk Stratification Marker That Reveals Platelet-Lipid Interplay in Coronary Artery Disease PatientsShakeel Kautbally, Sophie Lepropre, Marie-Blanche Onselaer, et al.
JAMA Cardiology|September 20, 2023
Repurposing the β3-Adrenergic Receptor Agonist Mirabegron in Patients With Structural Cardiac Disease: The Beta3-LVH Phase 2b Randomized Clinical TrialJean-Luc Balligand, Dulce Brito, Oana Brosteanu, et al.
European Heart Journal. Cardiovascular Imaging|January 10, 2024
Cardiovascular multimodality imaging in women: a scientific statement of the European Association of Cardiovascular Imaging of the European Society of CardiologyAna G Almeida, Julia Grapsa, Alessia Gimelli, et al.
European Heart Journal. Imaging Methods and Practice|February 4, 2026
Rational and design of EACVI-MMVD study: an international registry on multimodality imaging for mixed and multiple valvular heart diseaseAlexandre Unger, Giulia Elena Mandoli, Danilo Neglia, et al.
Pageof 14

Showing results (111-120 of 138) with videos related to

Sort By:
Pageof 14
The Lancet. Haematology|July 2, 2022
Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trialStefano Barco, Davide Voci, Ulrike Held, et al.
Bone Marrow Transplantation|November 4, 2018
Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry studyGuido Ghilardi, Thomas Pabst, Barbara Jeker, et al.
American Journal of Hematology|June 8, 2026
Determinants of Long-Term Benefit From High Dose Melphalan With Autologous Stem Cell Transplant in AL AmyloidosisMaximilian J Steinhardt, Ute Hegenbart, Tamer Hellou, et al.
European Heart Journal. Cardiovascular Imaging|July 12, 2024
Survival loss linked to guideline-based indications for degenerative mitral regurgitation surgeryDavid Vancraeynest, Anne-Catherine Pouleur, Christophe de Meester, et al.
European Heart Journal. Cardiovascular Imaging|April 4, 2020
COVID-19 pandemic and cardiac imaging: EACVI recommendations on precautions, indications, prioritization, and protection for patients and healthcare personnelHelge Skulstad, Bernard Cosyns, Bogdan A Popescu, et al.
Thrombosis Research|November 17, 2022
Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trialDavide Voci, Andrea Götschi, Ulrike Held, et al.
JACC. Basic to Translational Science|November 27, 2019
Platelet Acetyl-CoA Carboxylase Phosphorylation: A Risk Stratification Marker That Reveals Platelet-Lipid Interplay in Coronary Artery Disease PatientsShakeel Kautbally, Sophie Lepropre, Marie-Blanche Onselaer, et al.
JAMA Cardiology|September 20, 2023
Repurposing the β3-Adrenergic Receptor Agonist Mirabegron in Patients With Structural Cardiac Disease: The Beta3-LVH Phase 2b Randomized Clinical TrialJean-Luc Balligand, Dulce Brito, Oana Brosteanu, et al.
European Heart Journal. Cardiovascular Imaging|January 10, 2024
Cardiovascular multimodality imaging in women: a scientific statement of the European Association of Cardiovascular Imaging of the European Society of CardiologyAna G Almeida, Julia Grapsa, Alessia Gimelli, et al.
European Heart Journal. Imaging Methods and Practice|February 4, 2026
Rational and design of EACVI-MMVD study: an international registry on multimodality imaging for mixed and multiple valvular heart diseaseAlexandre Unger, Giulia Elena Mandoli, Danilo Neglia, et al.
Pageof 14